GLP 1 shot may be able to help you lose weight and keep it off
Abstract GLP-1 receptor agonists represent a breakthrough for managing type-2 diabetes and obesity, offering metabolic benefits across multiple organ systems
People are wondering if it will be better than semaglutide and tirzepatide
Retatrutide is a new weight management drug manufactured by Eli Lilly and Company for the treatment of obesity
The pharmaceutical landscape is currently witnessing a tectonic shift driven by the explosion of GLP-1 (Glucagon-Like Peptide-1) receptor agonists like semaglutide and tirzepatide
Its triple GIP/GLP-1/glucagon agonist mechanism produced the most striking weight-loss numbers ever reported in a Phase 2 trial of an injectable peptide, and its broad TRIUMPH Phase 3 program is poised to expand understanding of how triple receptor modulation affects obesity, diabetes, liver disease, cardiovascular risk, sleep apnea, and musculoskeletal health
